Today #BoltBio reported financial results for the fourth quarter & full year 2025 and provided corporate updates. Learn more: bit.ly/4ryDCO7

Our team is looking forward to attending the 46th Annual Health Care Conference hosted by TD Securities, as well as the Global Healthcare Conference hosted by Leerink Partners next month. Learn more about our participation in today's press release: bit.ly/4s8Bjlx

Today #BoltBio reported financial results for the third quarter and provided corporate updates. Learn more: bit.ly/4oDchcZ

Live from #SITC25: Justin Kenkel, PhD (@BoltBio) presents a novel PD-L1–directed Immune Stimulatory Antibody Conjugate (ISAC) that activates both innate and adaptive immunity to fight cancer. Key takeaways: • Unlike standard PD-L1 blockers, this ISAC delivers a TLR agonist to PD-L1⁺ myeloid cells, activating macrophages and dendritic cells. • Induces cytokine release and repolarizes the tumor microenvironment from immunosuppressive to immune-stimulatory. • Promotes T-cell priming and durable anti-tumor responses in preclinical models. • Offers a promising strategy to overcome resistance to current PD-1/PD-L1 therapies. #MoffittSITC25 @sitcancer

Today #BoltBio reported financial results for the second quarter and provided corporate updates. Learn more: bit.ly/3Uumdbe

Today #BoltBio reported financial results for the first quarter and provided corporate updates. Learn more: bit.ly/4kdiOrU

Join us at 2:30pm PT / 5:30pm ET today for a webcast KOL event discussing the Phase 1 dose-escalation results from our clinical study of BDC-3042. Our team will also share an update on our collaborations and clinical development plans. Tune in here: bit.ly/3Svalob

Join us on Monday, May 12, 2025, for a webcast KOL event discussing the Phase 1 dose-escalation results from our clinical study of BDC-3042. Our team will also share an update on our collaborations and clinical development plan for BDC-4182. Learn more: bit.ly/4dedLWg

Today, we're presenting data from our next-generation Boltbody™ #ISACs targeting CEA and PD-L1 at #AACR25! We're encouraged by these early results and are excited about this compelling new approach to treat #cancer. Read our press release here: bit.ly/42D9Oqr

We're at #AACR25 presenting data from our Phase 1 dose-escalation study of BDC-3042. We’re also sharing data from our PD-L1 targeting #antibody and CEA-targeted #ISAC programs. Stop by our posters to learn more and read the BDC-3042 press release here: bit.ly/4jMHLKy

We're presenting data from our Phase 1 dose-escalation clinical study of BDC-3042 at the @AACR annual meeting! Read our press release for more details on our poster presentations: bit.ly/4c1FWa2. #AACR25 #immunooncology #colorectalcancer #lungcancer #pancreaticcancer

Today #BoltBio reported financial results for the fourth quarter & full year 2024 and provided corporate updates. Learn more: bit.ly/4j0aMCs

According to @AmericanCancer, #ColorectalCancer is the 3rd most common cancer worldwide. At Bolt, we’re developing our dectin-2 targeting antibody, BDC-3042, for the potential treatment of CRC. Learn more about our work: boltbio.com

Today with our collaborators at Toray Industries, we announced that the target of our worldwide co-development collaboration is Toray-discovered Caprin-1. This co-developed Boltbody™ #ISAC will be applicable to multiple solid tumor types. Learn more: bit.ly/40MBK92

Today, #BoltBio commemorates #MLKDay. We are continuously inspired by Dr. King’s commitment to justice and challenge ourselves to examine ways we can contribute to creating a more equitable world both professionally and personally.

Our team is looking forward to being in San Francisco for #JPMWeek to connect with the #biotech community and discuss our novel immunotherapies for the treatment of #cancer. #ISAC #ImmunoOncology #JPM25

From our #TeamBolt family to yours, we’re wishing you a happy, healthy, and safe holiday season! Thank you for following our story as we progress our mission to leverage the immune system for a better way to treat cancer. Here's to an exciting 2025!

Earlier this month, our Senior Director and Program Team Lead, Shelley Ackerman, presented the advantages of next-generation #ISACs at @World_ADC San Diego conference! #TeamBolt #CancerResearch #Immunooncology

Today #BoltBio reported financial results for the third quarter and provided corporate updates. Learn more: bit.ly/4fqJ7sQ

September 24th is #WorldCancerResearchDay! Our talented team at #BoltBio is dedicated to the discovery and development of transformative treatments that leverage the immune system for a better way to treat cancer. Learn more about our science: bit.ly/3VunkZR